Revotar Biopharmaceuticals AG appointed Dr. Gerhard Wolff, M.D. as Vice President Research & Development
Revotar Biopharmaceuticals AG announced the appointment of Dr. Gerhard Wolff, M.D. as Executive Vice President, Research & Development of the company.
Dr. Wolff is a Board certified physician with specialty in Internal Medicine. He received his medical degree in 1992 from the University of Leipzig, Germany and postgraduate training in molecular medicine at the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany, the Heart, Lung and Blood Institute at the National Institute of Health, Bethesda Maryland and at the Weill Medical College, Cornell University New York, USA. Currently, he holds associate lecturer positions at the University of Applied Science of Berlin and at the Charité of the Humboldt-University of Berlin, Germany. In parallel to his academic career, he participated and headed preclinical and clinical development projects with several pharmaceutical companies including Genzyme, Genentech, GenVec, Hoechst, or Schering AG. In 2002
Dr. Wolff joined Revotar as Director Development to conduct the clinical development program of bimosiamose, the first-in-class selectin antagonist and Revotar's leading product. Upon the success of the clinical program and the progress of the corresponding discovery projects, Revotar created the new position to coordinate and synergize the activities of discovery and development of selectin antagonists.
Other news from the department people
